Oxford Nanopore Technologies PLC secures injunction against MGI Tech

Oxford Nanopore Technologies PLC (OTC: ONTTF) announced that it has obtained an injunction from a UK court against MGI Tech, the Chinese genomics firm, in a patent dispute. The injunction was granted on 16 September 2026 and bars MGI Tech from using, copying or distributing the patented technology that Oxford Nanopore claims it owns. The decision follows a series of filings by Oxford Nanopore that allege infringement of multiple patents covering its nanopore sequencing platforms.

The ruling is expected to limit MGI Tech’s ability to offer competing sequencing solutions in the UK market and may influence the broader competitive landscape for portable DNA sequencing devices. Oxford Nanopore’s legal team stated that the injunction protects the company’s intellectual property portfolio and reinforces its position as a leader in molecular detection and analysis.

Market context and company outlook

Oxford Nanopore Technologies is listed on the London Stock Exchange and trades in GBX. As of 14 September 2026 the closing price stood at 158.3 GBX, within a 52‑week range of 95.7 to 191.4 GBX. The company’s market capitalisation is approximately 2.07 billion GBX. Its price‑to‑earnings ratio is negative, at –12.839, reflecting the company’s investment‑heavy growth strategy.

The company’s primary products—nanopore sequencing devices and associated reagents—serve a wide array of applications, including DNA sequencing, diagnostics, drug development, biomolecular interaction studies, ion‑channel screening and defence. Oxford Nanopore’s technology enables real‑time, single‑molecule analysis, which is increasingly valuable for rapid diagnostics and research.

In September 2026, Oxford Nanopore participated in the Morgan Stanley Global Healthcare Conference, where it presented updates on product development and market strategy. The company’s inclusion in the conference transcript underscores its relevance to investors focused on healthcare technology.

The global PCR technologies market is projected to grow to USD 21.43 billion by 2031, up from USD 15.55 billion in 2026, according to a MarketsandMarkets report released on 15 September 2026. While PCR and nanopore technologies serve different niches—PCR focuses on amplification and detection, whereas nanopore offers sequencing—the two markets are complementary. Oxford Nanopore’s continued innovation may capture a share of the expanding molecular diagnostics sector.

Other UK technology firms have faced challenges. A Bloomberg article from 13 September 2026 highlighted difficulties for UK tech spinouts outside the Golden Triangle, noting that many have struggled to secure sustained funding and market traction. This environment underscores the importance of strong intellectual property protection for companies like Oxford Nanopore.

Ancillary corporate activity

Oxford Nanopore’s former chief executive, Dr. Gordon Sanghera, joined the advisory board of Aitiologic, a start‑up focused on tissue‑resolved liquid biopsy. Aitiologic’s seed round, raised in September 2026, was oversubscribed and received backing from Heal Capital and Ananda Impact Ventures. Dr. Sanghera’s involvement reflects Oxford Nanopore’s broader engagement with the diagnostics ecosystem.

The information provided here is based solely on the supplied financial data and news items. No additional sources were consulted.